Yes, under the radar and soon to be a missed opportunity IMO. The science continues to unfold at each step with better than expected results each time. For both cancer and autoimmunity. They have not staffed the advisory board with top talent for no reason. It works that is bottom line thus far. GL.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.